Basic research by Dr. Brian Druker @OHSUKnight in the 1990s contributed to the development of #imatinib (Gleevec), a landmark drug that has improved the outcomes of patients with #chronicmyelogenousleukemia. cancer.gov/research/progr… #NothingWillStopUs 
He discovered that a compound called STI-571 (a.k.a #imatinib) specifically inhibits growth and tumor formation by #leukemia cells expressing BCR-ABL (a fusion oncoprotein that drives #chronicmyelogenousleukemia) in an @theNCI funded @NatureMedicine study. nature.com/articles/nm059…
Based on these findings, Dr. Druker et al. tested #imatinib in a phase 1 #clinicaltrial. They found that the drug was well tolerated and an effective treatment against #chronicmyelogenousleukemia in patients with late-stage disease. nejm.org/doi/10.1056/NE… #NothingWillStopUs
In 2001, @US_FDA approved #imatinib to treat patients with BCR-ABL driven #chronicmyelogenousleukemia. fda.gov/drugs/postmark… #NothingWillStopUs
Further, an @ASCO_pubs article showed that the life expectancy of patients with #chronicmyelogenousleukemia treated with #imatinib approaches that of the general population. ascopubs.org/doi/full/10.12… #NothingWillStopUs
In summary, the basic research of Dr. Druker investigating biological mechanisms of cancer laid the foundation for the development of a clinical #cancertherapy that transformed the treatment of #chronicmyelogenousleukemia. cancer.gov/research/progr… #NothingWillStopUs
• • •
Missing some Tweet in this thread? You can try to
force a refresh
